Aggarwal, S K, Carter, G T, Sullivan, M D, ZumBrunnen, C, Morrill, R & Mayer, J D. (2009). Medicinal use of cannabis in the United States: historical perspectives, current trends, and future direction. J Opioid Manag 5, 153–168.
Al-Dahmani, K, Mohammad, S, Imran, F et al. (2016). Sellar masses: An epidemiological study. Can J Neurol Sci 43, 291–297.
Assies, J, Schellekens, A P & Touber, J L. (1980). The value of an intravenous TRH test for the diagnosis of tumoural prolactinaemia. Acta Endocr 94, 439–449.
Athanasoulia-Kaspar, A P, Popp, K H & Stalla, G K. (2018). Neuropsychiatric and metabolic aspects of dopaminergic therapy: perspectives from an endocrinologist and a psychiatrist. Endocr Connections 7, R88–R94.
Aydin, S, Dag, E, Ozkan, Y et al. (2011). Time-dependent changes in the serum levels of prolactin, nesfatin-1 and ghrelin as a marker of epileptic attacks young male patients. Peptides 32, 1276–1280.
Barni, S, Lissoni, P, Paolorossi, F et al. (1987). Effects of radical mastectomy on prolactin blood levels in patients with breast cancer. Europ J Cancer Oncol 23, 1141–1145.
Ben-Jonathan, B & Hnasko, R. (2001). Dopamine as a prolactin (PRL) inhibitor. Endocr Revs 22, 724–763.
Ben-Jonathan, N, LaPensee, C R & LaPensee, E W. (2008). What can we learn from rodents about prolactin in humans? Endocr Revs 29, 1–41.
Bernard, V, Young, J, Chanson, P & Binart, N. (2015). New insights in prolactin: pathological implications. Nat Revs Endocr 11, 265–275.
Brennan, M J. (2013). The effect of opioid therapy on endocrine function. Am J Med 126, S12–S18.
Caufriez, A, Leproult, R, L’Hermite-Baleriaux, M, Moreno-Reyes, R & Copinschi, G. (2009). A potential role of endogenous progesterone in modulation of GH, prolactin and thyrotrophin secretion during normal menstrual cycle. Clin Endocr 71, 535–542.
Cuny, T, Barlier, A, Feelders, R et al. (2015). Medical therapies in pituitary adenomas: current rationale for the use and future perspectives. Annales d’Endocr 76, 43–58.
Doknic, M, Pekic, S, Zarkovic, M et al. (2002). Dopaminergic tone and obesity: an insight from prolactinomas treated with bromocriptine. Europ J Endocr 147, 77–84.
Dudas, B, Baker, M, Rotoli, G, Grignol, G, Bohn, M C & Merchenthaler, I. (2010). Distribution and morphology of the catecholaminergic neural elements in the human hypothalamus. Neurosci 171, 187–195.
Ehara, Y, Siler, T M & Yen, S S C. (1976). Effects of high doses of estrogen on prolactin and growth hormone release. Am J Obstet Gynecol 125, 455–458.
Eisenstein, S A, Antenor-Dorsey, J A V, Gredysa, D M et al. (2013). A comparison of D2 receptor specific binding in obese and normal-weight individuals using PET with (N-[11 C] methyl)benperidol. Synapse 67, 748–756.
Exton, M S, Kruger, T H C, Koch, M et al. (2001). Coitus-induced orgasm stimulates prolactin secretion in healthy subjects. Psychoneuroendocr 26, 287–294.
Fahie-Wilson, M & Smith, T P. (2013). Determination of prolactin: the macroprolactin problem. Best Pract Res Clin Endocr Metab 27, 725–742.
Freeman, M E, Kanyicska, B, Lerant, A & Nagy, G. (2000). Prolactin: structure, function, and regulation of secretion. Physiol Revs 80, 1523–1631.
Freemark, M, Fleenor, D, Driscoll, P, Binart, N & Kelly, P A. (2001). Body weight and fat deposition in prolactin receptor-deficient mice. Endocr 142, 532–537.
Fusco, A, Lugli, F, Sacco, E et al. (2011). Efficacy of the combined cabergoline and octreotide treatment in a case of a dopamine-agonist resistant macroprolactinoma. Pituitary 14, 351–357.
Garas, A, Trypsianis, G, Kallitsaris, A, Milingos, S & Messinis, I E. (2006). Oestradiol stimulates prolactin secretion in women through oestrogen receptors. Clin Endocr 65, 638–642.
Garin, M C, Burns, C M, Kaul, S & Cappola, A R. (2013). The human experience with ghrelin administration. J Clin Endocr Metab 98, 1826–1837.
Gautvik, K M, Tashjian, A H, Kourides, I A et al. (1974). Thyrotropin-releasing hormone is not the sole physiological mediator of prolactin release during suckling. New Engl J Med 290, 1162–1165.
Gehlbach, D L, Bayliss, P & Rosa, C. (1989). Prolactin and thyrotropin responses to nursing during the puerperium. J Reprod Med 34, 295–298.
Gomez-Merino, D, Drogou, C, Chennaoui, M, Tiollier, E, Mathieu, J & Guezennec, C Y. (2005). Effects of combined stress during intense training on cellular immunity, hormones and respiratory infections. Neuroimmunomod 12, 164–172.
Goyal, N, Gore, M A & Shankar, R. (2008). Galactorrhea and amenorrhea in burn patients. Burns 34, 825–828.
Greenman, Y, Tordjman, K & Stern, N. (1998). Increased body weight associated with prolactin secreting pituitary adenomas: weight loss with normalization of prolactin levels. Clin Endocr 48, 547–553.
Hackney, A C, Davis, H C & Lane, A R. (2015). Exercise augments the nocturnal prolactin rise in exercise-trained men. Therap Adv Endocr Metab 6, 217–222.
Haddad, P M & Wieck, A. (2004). Antipsychotic-induced hyperprolactinaemia: mechanisms, clinical features and management. Drugs 64, 2291–2314.
Harmon, J & Aliapoulios, M D. (1972). Gynecomastia in marihuana users. N Engl J Med 287, 936.
Harvey, S, Martínez-Moreno, C G, Luna, M & Arámburo, C. (2015). Autocrine/paracrine roles of extrapituitary growth hormone and prolactin in health and disease: an overview. Gen Comp Endocr 220, 103–111.
Heaney, AP & Melmed, S. (2004). Molecular targets in pituitary tumours. Nature Revs Cancer 4, 285–295.
Hekimsoy, Z, Kafesçiler, S, Güçlü, F & Özmen, B. (2010). The prevalence of hyperprolactinaemia in overt and subclinical hypothyroidism. Endocr J 57, 1011–1015.
Hillard, C J. (2015). Endocannabinoids and the endocrine system in health and disease. Handb Exp Pharmacol 231, 317–339.
Jacobs, L S, Snyder, P J, Wilber, J F, Utiger, R D & Daughaday, W H. (1971). Increased serum prolactin after administration of synthetic thyrotropin releasing hormone (TRH) in man. J Clin Endocr Metab 33, 996–998.
Jaquet, P, Ouafik, L, Saveanu, A et al. (1999). Quantitative and functional expression of somatostatin receptor subtypes in human prolactinomas. J Clin Endocr Metab 84, 3268–3276.
Kalleinen, N, Polo-Kantola, P, Irjala, K et al. (2008). 24-hour serum levels of growth hormone, prolactin, and cortisol in pre- and postmenopausal women: the effect of combined estrogen and progestin treatment. J Clin Endocr Metab 93, 1655–1661.
Karaca, Z, Tanriverdi, F, Unluhizarci, K & Kelestimur, F. (2010). Pregnancy and pituitary disorders. Eur J Endocr 162, 453–475.
Katsuren, E, Ishikawa, S, Honda, K & Saito, T. (1997). Galactorrhoea and amenorrhoea due to an intradural neurinoma originating from a thoracic intercostal nerve radicle. Clin Endocr 46, 631–636.
Kok, P, Roelfsema, F, Frölich, M, Meinders, A E & Pijl, H. (2004). Prolactin release is enhanced in proportion to excess visceral fat in obese women. J Clin Endocr Metab 89, 4445–4449.
Kok, P, Roelfsema, F, Langendonk, J G et al. (2006). Increased circadian prolactin release is blunted after body weight loss in obese premenopausal women. Am J Physiol Endocr Metab 290, E218–E224.
Kopelman, P G. (2000). Physiopathology of prolactin secretion in obesity. Int J Obes Relat Metab Disorders 24, Suppl 2, S104–S108.
Kovacs, K, Horvath, E, Syro, L V et al. (2007). Temozolomide therapy in a man with an aggressive prolactin-secreting pituitary neoplasm: morphological findings. Hum Pathol 38, 185–189.
Krüger, T H C, Hartmann, U & Schedlowski, M. (2005). Prolactinergic and dopaminergic mechanisms underlying sexual arousal and orgasm in humans. World J Urol 23, 130–138.
Labad, J, Stojanovic-Perez, A, Montalvo, I et al. (2015). Stress biomarkers as predictors of transition to psychosis in at-risk mental states: Roles for cortisol, prolactin and albumin. J Psych Res 60, 163–169.
Latta, F, Leproult, R, Tasali, E et al. (2005). Sex differences in nocturnal growth hormone and prolactin secretion in healthy older adults: relationships with sleep EEG variables. Sleep 28, 1519–1524.
Lennartsson, A-K & Jonsdottir, I H. (2011). Prolactin in response to acute psychosocial stress in healthy men and women. Psychoneuroendocr 36, 1530–1539.
Macrea, M M, Martin, T J & Zagrean, L. (2010). Infertility and obstructive sleep apnea: the effect of continuous positive airway pressure therapy on serum prolactin levels. Sleep Breath 14, 253–257.
Maggi, M, Buvat, J, Corona, G, Guay, A & Torres, L O. (2013). Hormonal causes of male sexual dysfunctions and their management (hyperprolactinemia, thyroid disorders, GH disorders, and DHEA). J Sex Med 10, 661–677.
Malarkey, W B, Hall, J C, Pearl, D K, Kiecolt-Glaser, J K & Glaser, R. (1991). The influence of academic stress and season on 24-hour concentrations of growth hormone and prolactin. J Clin Endocr Metab 73, 1089–1092.
Marano, R J & Ben-Jonathan, N. (2014). Minireview: Extrapituitary prolactin: an update on the distribution, regulation, and functions. Mol Endocr 28, 622–633.
Maule, W J. (2015). Medical uses of marijuana (Cannabis sativa): fact or fallacy? Br J Biomed Sci 72, 85–91.
McNeilly, A S. (2001). Lactational control of reproduction. Reprod Fertil Dev 13, 583–590.
Melmed, S & Kleinberg, D. (2008). Anterior pituitary. In: Williams Textbook of Endocrinology, 11th Edition. Kronenberg, H M, Melmed, S, Polonsky, K S & Larsen, P R, Eds. (Philadelphia: Saunders Elsevier), 185.
Merdin, A, Merdin, FA, Gündüz, S, Bozcuk, H & Coşkun, H S. (2016). Opioid endocrinopathy: a clinical problem in patients with cancer pain. Exp Therap Med 11, 1819–1822.
Morley, J E, Dawson, M, Hodgkinson, H & Kalk, W J. (1977). Galactorrhea and hyperprolactinemia associated with chest wall injury. J Clin Endocr Metab 45, 931–935.
Newey, PJ, Gorvin, CM, Cleland, SJ et al. (2013). Mutant prolactin receptor and familial hyperprolactinemia. N Engl J Med 369, 2012–2020.
Newey, P J, Gorvin, C M & Thakker, R V. (2014). Mutant prolactin receptor and familial hyperprolactinemia. N Engl J Med 370, 977–978.
Nicoletti, I, Filipponi, P, Fedeli, L, Ambrosi, F, Gregorini, G & Santeusanio, F. (1984). Testosterone-induced hyperprolactinaemia in a patient with a disturbance of hypothalamo-pituitary regulation. Acta Endocr 105, 167–172.
Noel, G L, Suh, H K, Stone, J G & Frantz, A G. (1972). Human prolactin and growth hormone release during surgery and other conditions of stress. J Clin Endocr Metab 35, 840–851.
Noel, G L, Suh, H K & Frantz, A G. (1974). Prolactin release during nursing and breast stimulation in postpartum and non-postpartum subjects. J Clin Endocr Metab 38, 413–423.
Normandin, M D, Zheng, M-Q, Lin, K-S et al. (2015). Imaging the cannabinoid CB1 receptor in humans with [11 C] OMAR: assessment of kinetic analysis methods, test–retest reproducibility, and gender differences. J Cerebral Blood Flow 35, 1313–1322.
Olafsdottir, A & Schlechte, J. (2006). Management of resistant prolactinomas. Nat Clin Pract Endocr Metab 2, 552–561.
Pagotto, U, Marsicano, G, Fezza, F et al. (2001). Normal human pituitary gland and pituitary adenomas express cannabinoid receptor type 1 and synthesize endogenous cannabinoids: first evidence for a direct role of cannabinoids on hormone modulation at the human pituitary level. J Clin Endocr Metab 86, 2687–2696.
Palkovits, M, Harvey-White, J, Liub, J et al. (2008). Regional distribution and effects of postmortal delay on endocannabinoid content of the human brain. Neurosci 152, 1032–1039.
Pivonello, R, Waaijers, M, Kros, J M et al. (2016). Dopamine D2 receptor expression in the corticotroph cells of the human normal pituitary gland. Endocrine 57, 314–325.
Ranganathan, M, Braley, G, Pittman, B et al. (2009). The effects of cannabinoids on serum cortisol and prolactin in humans. Psychopharmacol 203, 737–744.
Rhodin, A, Stridsberg, M & Gordh, T. (2010). Opioid endocrinopathy: a clinical problem in patients with chronic pain and long-term oral opioid treatment. Clin J Pain 26, 374–380.
Roelfsema, F, Pijl, H, Keenan, D M & Veldhuis, J D. (2012). Prolactin secretion in healthy adults is determined by gender, age and body mass index. PLoS One 7, e31305.
Rojas Vega, S, Hollmann, W & Strüder, H K. (2011). Influences of exercise and training on the circulating concentration of prolactin in humans. J Neuroendocr 24, 395–402.
Samson, S L, Hamrahian, A H & Ezzat, S. (2015). Clinical relevance of macroprolactin in the absence or presence of true hyperprolactinemia. Endocr Pract 21, 1427–1435.
Saraç, F P, Ozgen, A G, Saygili, F & Yilmaz, C. (2008). Prolactin levels and examination with breast ultrasound or mammography. Adv Therap 25, 59–66.
Sathyapalan, T, González, S & Atkin, S L. (2009). Effect of long-term, high-dose estrogen treatment on prolactin levels: a retrospective analysis. Climacteric 12, 427–430.
Scheithauer, B W, Sano, T, Kovacs, K T, Young, W F Jr, Ryan, N & Randall, R V. (1990). The pituitary gland in pregnancy: a clinicopathologic and immunohistochemical study of 69 cases. Mayo Clin Proc 65, 461–474.
Sodi, R, Fikri, R, Diver, M, Ranganath, L & Vora, J. (2005). Testosterone replacement-induced hyperprolactinaemia: case report and review of the literature. Ann Clin Biochem 42, 153–159.
Stokes, K A, Gilbert, K L, Hall, G M, Andrews, R C & Thompson, D. (2013). Different responses of selected hormones to three types of exercise in young men. Eur J Appl Physiol 113, 775–783.
Tanner, M J, Hadlow, N C & Wardrop, R. (2011). Variation of female prolactin levels with menopausal status and phase of menstrual cycle. Aust NZ J Obs Gyn 51, 321–324.
Tay, C C K, Glasier, A F & McNeilly, A S. (1996). Twenty-four hour patterns of prolactin secretion during lactation and the relationship to suckling and the resumption of fertility in breast-feeding women. Hum Reprod 11, 950–955.
Tikk, K, Sookthai, D, Johnson, T et al. (2014). Prolactin determinants in healthy women: a large cross-sectional study within the EPIC cohort. Cancer Epidemiol Biomarkers Prev 23, 2532–2542.
Veldhuis, J D, Iranmanesh, A, Johnson, M L & Lizarralde, G. (1990). Twenty-four-hour rhythms in plasma concentrations of adenohypophyseal hormones are generated by distinct amplitude and/or frequency modulation of underlying pituitary secretory bursts. J Clin Endocr Metab 71, 1616–1623.
Verhelst, J, Abs, R, Maiter, D et al. (1999). Cabergoline in the treatment of hyperprolactinemia: A study in 455 patients. J Clin Endocr Metab 84, 2518–2522.
Veselinovic, T, Schorn, H, Vernaleken, I B, Schiffl, K, Klomp, M & Grunder, G. (2011). Impact of different antidopaminergic mechanisms on the dopaminergic control of prolactin secretion. J Clin Psychopharmacol 31, 214–220.
Voicu, V, Medvedovici, A, Ranetti, A E & Radulescu, F S. (2013). Drug-induced hypo- and hyperprolactinemia: mechanisms, clinical and therapeutic consequences. Exp Opin Drug Metab Toxicol 9, 955–968.
Volkow, N D & McLellan, A T. (2016). Opioid abuse in chronic pain: Misconceptions and mitigation strategies. New Engl J Med 375, 1253–1263.
Vuong, C, Van Uum, S H M, O’Dell, L E, Lutfy, K & Friedman, T C. (2010). The effects of opioids and opioid analogs on animal and human endocrine systems. Endocr Revs 31, 98–132.
Webster, J, Piscitelli, G, Polli, A, Ferrari, C I, Ismail, I & Scanlon, M F. (1994). A comparison of cabergoline and bromocriptine in the treatment of hyperprolactinemic amenorrhea. New Engl J Med 331, 904–909.
Weikel, JC, Wichniak, A, Ising, M et al. (2003). Ghrelin promotes slow-wave sleep in humans. Am J Physiol Endocr Metab 284, E407–E415.
Wierman, M E, Nappi, R E, Avis, N et al. (2010). Endocrine aspects of women’s sexual function. J Sex Med 7, 561–585.
Wong, D, Gray, D P, Simmonds, M, Rashiq, S, Sobolev, I & Morrish, D W. (2011). Opioid analgesics suppress male gonadal function, but opioid use in men and women does not correlate with symptoms of sexual dysfunction. Pain Res Manag 16, 311–316.
Wong, A, Anderson Eloy, J, Couldwell, W T & Liu, J K. (2015). Update on prolactinomas. Part 2: Treatment and management strategies. J Clin Neurosci 22, 1568–1574.
Yasuo, S, Unfried, C, Kettner, M, Geisslinger, G & Korf, H W. (2010). Localization of an endocannabinoid system in the hypophysial pars tuberalis and pars distalis of man. Cell Tissue Res 342, 273–281.